Literature DB >> 16842390

Facial thermography is a sensitive tool to determine antihistaminic activity: comparison of levocetirizine and fexofenadine.

Michael Larbig1, Bernard Burtin, Laurent Martin, Holger Stamm, Birgit Luettig, Jens M Hohlfeld, Norbert Krug.   

Abstract

AIMS: To assess the antihistaminic activity of levocetirizine and fexofenadine 2 h and 24 h after drug administration using facial thermography and to compare the results with those using well-established parameters of antihistaminic activity in the nose and skin.
METHODS: This was a randomized, double-blind, three-treatment, three-period, single-dose, cross-over study in healthy males taking levocetirizine 5 mg, fexofenadine 120 mg or placebo. The primary endpoint was nasal skin temperature after nasal histamine challenge recorded for 20 min at 2 and 24 h after drug intake. The secondary endpoints were nasal symptoms and a histamine skin prick test.
RESULTS: Thirty subjects were randomized. At 2 h after drug intake the inhibition of the nasal temperature increase from baseline was not significantly different between levocetirizine and fexofenadine. At 24 h it was significantly more pronounced after levocetirizine than fexofenadine (difference: least-squares mean: -0.13 degrees C; P < or = 0.024, 95% CI -0.24, -0.02). Both drugs significantly reduced (P < or = 0.001) the mean temperature increase from baseline compared with placebo at 2 and 24 h (least-squares mean increase and (95% CI): levocetirizine, -0.28 degrees C (-0.42, -0.14) and -0.32 degrees C (-0.43, -0.21); fexofenadine -0.35 degrees C (-0.49, -0.21) and -0.19 degrees C (-0.30, -0.08), respectively). Results of nasal symptom score and wheal and flare were consistent with the thermography results.
CONCLUSIONS: Facial thermography is an objective, non-invasive and sensitive method to study antihistaminic activity at the nose level. Levocetirizine and fexofenadine demonstrate the same activity at 2 h after drug intake, but levocetirizine has a more sustained activity at 24 h.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16842390      PMCID: PMC1885088          DOI: 10.1111/j.1365-2125.2006.02647.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

Review 1.  Clinical pharmacology of H1-antihistamines.

Authors:  F Estelle R Simons; Keith J Simons
Journal:  Clin Allergy Immunol       Date:  2002

2.  Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria.

Authors:  K Simpson; B Jarvis
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

3.  Histamine H1 receptor occupancy and pharmacodynamics of second generation H1-antihistamines.

Authors:  M Gillard; M Strolin Benedetti; P Chatelain; E Baltes
Journal:  Inflamm Res       Date:  2005-09       Impact factor: 4.575

4.  A comparison of once daily fexofenadine versus the combination of montelukast plus loratadine on domiciliary nasal peak flow and symptoms in seasonal allergic rhinitis.

Authors:  A M Wilson; L C Orr; W J R Coutie; E J Sims; B J Lipworth
Journal:  Clin Exp Allergy       Date:  2002-01       Impact factor: 5.018

5.  A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects.

Authors:  J Andrew Grant; Jean-Michel Riethuisen; Béatrice Moulaert; Christine DeVos
Journal:  Ann Allergy Asthma Immunol       Date:  2002-02       Impact factor: 6.347

6.  Comparison of five new antihistamines (H1-receptor antagonists) in patients with allergic rhinitis using nasal provocation studies and skin tests.

Authors:  J van Steekelenburg; P A R Clement; M H L Beel
Journal:  Allergy       Date:  2002-04       Impact factor: 13.146

7.  Controlled comparison of the efficacy and safety of cetirizine 10 mg o.d. and fexofenadine 120 mg o.d. in reducing symptoms of seasonal allergic rhinitis.

Authors:  F Horak; P Stübner; R Zieglmayer; A Kavina; C De Vos; B Burtin; F Donnelly
Journal:  Int Arch Allergy Immunol       Date:  2001-05       Impact factor: 2.749

8.  Twenty-four hours of activity of cetirizine and fexofenadine in the skin.

Authors:  A Purohit; C Duvernelle; M Melac; G Pauli; N Frossard
Journal:  Ann Allergy Asthma Immunol       Date:  2001-04       Impact factor: 6.347

9.  Relative potency of fexofenadine HCl 180 mg, loratadine 10 mg, and placebo using a skin test model of wheal-and-flare suppression.

Authors:  Michael A Kaliner; Martha V White; Athena Economides; Tera Crisalida; Mary Hale; Yuning Liao; Claire D Christian; George C Georges; Thomas H Woodworth; Suzanne G Meeves
Journal:  Ann Allergy Asthma Immunol       Date:  2003-06       Impact factor: 6.347

Review 10.  Histamine in the immune regulation of allergic inflammation.

Authors:  Cezmi A Akdis; Kurt Blaser
Journal:  J Allergy Clin Immunol       Date:  2003-07       Impact factor: 10.793

View more
  5 in total

1.  Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy.

Authors:  Lawrence DuBuske; Krzysztof Kowal
Journal:  Curr Allergy Asthma Rep       Date:  2009-03       Impact factor: 4.806

2.  Once daily levocetirizine for the treatment of allergic rhinitis and chronic idiopathic urticaria.

Authors:  E Nettis; G F Calogiuri; E Di Leo; F Cardinale; L Macchia; A Ferrannini; A Vacca
Journal:  J Asthma Allergy       Date:  2008-12-16

3.  Investigation of the antiallergic activity of olopatadine on rhinitis induced by intranasal instillation of antigen in sensitized rats using thermography.

Authors:  Tadafumi Tamura
Journal:  Asia Pac Allergy       Date:  2011-09-29

4.  Halo formations around senile hemangiomas in diffuse plane normolipemic xanthomatosis associated with monoclonal gammopathy.

Authors:  Tokimasa Hida; Hiroki Takahashi; Kohichi Takada; Hisashi Uhara
Journal:  JAAD Case Rep       Date:  2018-11-10

5.  Antihistamine effects and safety of fexofenadine: a systematic review and Meta-analysis of randomized controlled trials.

Authors:  Cheng-Zhi Huang; Zhi-Hui Jiang; Jian Wang; Yue Luo; Hua Peng
Journal:  BMC Pharmacol Toxicol       Date:  2019-11-29       Impact factor: 2.483

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.